Published in Blood on November 18, 2004
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood (2009) 2.42
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood (2005) 1.63
Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. Leuk Lymphoma (2014) 1.50
FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat (2009) 1.47
Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev (2010) 1.42
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget (2012) 1.34
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant (2008) 1.27
mTORC1 is essential for leukemia propagation but not stem cell self-renewal. J Clin Invest (2012) 1.27
Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget (2011) 1.26
Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica (2009) 1.21
Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. Cell Cycle (2011) 1.10
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood (2008) 1.09
PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol (2007) 1.08
NF1 inactivation in adult acute myelogenous leukemia. Clin Cancer Res (2010) 1.08
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Mol Cell Ther (2015) 1.05
Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev (2010) 1.03
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. PLoS One (2013) 1.02
mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol Cancer (2010) 1.00
Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther (2009) 1.00
Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses. PLoS One (2009) 0.98
Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo. Blood (2005) 0.98
RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation. Exp Hematol (2007) 0.95
Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res (2009) 0.95
Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. Clin Cancer Res (2014) 0.92
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol Cancer (2013) 0.91
mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression. Leukemia (2013) 0.90
SYK regulates mTOR signaling in AML. Leukemia (2013) 0.90
The evolving landscape in the therapy of acute myeloid leukemia. Protein Cell (2013) 0.90
The PI-3kinase pathway in hematopoietic stem cells and leukemia-initiating cells: a mechanistic difference between normal and cancer stem cells. Blood Cells Mol Dis (2008) 0.89
Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment. J Cell Physiol (2009) 0.87
Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol (2015) 0.87
Acute myeloid leukaemia: optimal management and recent developments. Drugs (2011) 0.86
PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway. J Exp Clin Cancer Res (2008) 0.86
New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines. Curr Oncol Rep (2009) 0.86
Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Rev Hematol (2009) 0.85
The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation. Haematologica (2012) 0.85
Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives. Cancers (Basel) (2011) 0.85
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. Oncotarget (2015) 0.85
Evi1 forms a bridge between the epigenetic machinery and signaling pathways. Oncotarget (2011) 0.84
Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype. Cancer Biol Ther (2012) 0.83
Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. J Clin Med (2015) 0.82
Mammalian target of rapamycin activity is required for expansion of CD34+ hematopoietic progenitor cells. Haematologica (2009) 0.81
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Invest New Drugs (2013) 0.81
The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteins. Exp Ther Med (2013) 0.81
New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease. Br J Clin Pharmacol (2016) 0.81
Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia. Cancer Biol Ther (2015) 0.80
[Tumor stem cell research - basis and challenge for diagnosis and therapy]. Wien Klin Wochenschr (2010) 0.80
Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis. Bone Marrow Transplant (2014) 0.78
Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. Leukemia (2014) 0.77
Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition. Stem Cells Int (2015) 0.77
Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways. Int J Hematol Oncol (2013) 0.77
Effect of combination of rapamycin and cisplatin on human cervical carcinoma Hela cells. Contemp Oncol (Pozn) (2013) 0.77
Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia. Cytokine (2016) 0.77
Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab. Semin Hematol (2012) 0.77
Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells. Int J Clin Exp Med (2015) 0.76
Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia. J Hematol Oncol (2016) 0.76
Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia. Oncotarget (2016) 0.76
Co-activation of AMPK and mTORC1 as a new therapeutic option for acute myeloid leukemia. Mol Cell Oncol (2015) 0.75
Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia. J Hematol Oncol (2016) 0.75
Targeting leukemia stem cells: The new goal of therapy in adult acute myeloid leukemia. World J Stem Cells (2009) 0.75
Identification of key regulatory pathways of myeloid differentiation using an mESC-based karyotypically normal cell model. Blood (2012) 0.75
Prediction of drug indications based on chemical interactions and chemical similarities. Biomed Res Int (2015) 0.75
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. Oncotarget (2016) 0.75
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2010) 9.77
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol (2010) 8.80
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med (2005) 4.13
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell (2003) 3.36
Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol (2013) 3.10
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood (2010) 3.06
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood (2008) 2.39
Osh4p exchanges sterols for phosphatidylinositol 4-phosphate between lipid bilayers. J Cell Biol (2011) 2.22
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol (2008) 2.12
Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol (2004) 2.11
Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. Br J Haematol (2013) 2.03
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
Conversion of PtdIns(4,5)P(2) into PtdIns(5)P by the S.flexneri effector IpgD reorganizes host cell morphology. EMBO J (2002) 1.94
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res (2010) 1.93
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood (2012) 1.88
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood (2009) 1.84
Origin, originality, functions, subversions and molecular signalling of macropinocytosis. Int J Med Microbiol (2002) 1.72
Syk-dependent mTOR activation in follicular lymphoma cells. Blood (2006) 1.68
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood (2007) 1.67
The phosphoinositide kinase PIKfyve/Fab1p regulates terminal lysosome maturation in Caenorhabditis elegans. Mol Biol Cell (2006) 1.66
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene (2005) 1.64
Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol (2009) 1.64
Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood (2011) 1.62
Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leuk Res (2011) 1.61
Production of phosphatidylinositol 5-phosphate by the phosphoinositide 3-phosphatase myotubularin in mammalian cells. J Biol Chem (2003) 1.58
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience. Leuk Res (2011) 1.55
What lessons can be learned from γδ T cell-based cancer immunotherapy trials? Cell Mol Immunol (2012) 1.54
Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status. Leuk Res (2009) 1.52
The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood (2008) 1.48
The cell cycle regulator CDC25A is a target for JAK2V617F oncogene. Blood (2011) 1.47
Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res (2010) 1.47
PtdIns5P activates the host cell PI3-kinase/Akt pathway during Shigella flexneri infection. EMBO J (2006) 1.45
Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res (2004) 1.42
A critical role for Lyn in acute myeloid leukemia. Blood (2007) 1.40
SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias. Leuk Lymphoma (2012) 1.39
Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res (2004) 1.38
The phosphatidylinositol (PI)-5-phosphate 4-kinase type II enzyme controls insulin signaling by regulating PI-3,4,5-trisphosphate degradation. Proc Natl Acad Sci U S A (2003) 1.37
A novel PtdIns3P and PtdIns(3,5)P2 phosphatase with an inactivating variant in centronuclear myopathy. Hum Mol Genet (2006) 1.33
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood (2009) 1.31
Phosphoinositide signaling disorders in human diseases. FEBS Lett (2003) 1.29
Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol (2013) 1.26
Differential regulation of actin stress fiber assembly and proplatelet formation by alpha2beta1 integrin and GPVI in human megakaryocytes. Blood (2004) 1.25
Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood (2009) 1.24
Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood (2003) 1.22
Myotubularin controls desmin intermediate filament architecture and mitochondrial dynamics in human and mouse skeletal muscle. J Clin Invest (2010) 1.21
Acute leukemia during pregnancy: a report on 37 patients and a review of the literature. Cancer (2005) 1.20
mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle (2005) 1.19
Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene (2004) 1.19
Type II phosphatidylinositol 4-kinases promote Listeria monocytogenes entry into target cells. Cell Microbiol (2007) 1.18
Phosphatidylinositol 3-phosphate, an essential lipid in Plasmodium, localizes to the food vacuole membrane and the apicoplast. Eukaryot Cell (2010) 1.16
Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. J Clin Virol (2010) 1.16
Functional redundancy in the myotubularin family. Biochem Biophys Res Commun (2002) 1.15
Expression of myotubularin by an adenoviral vector demonstrates its function as a phosphatidylinositol 3-phosphate [PtdIns(3)P] phosphatase in muscle cell lines: involvement of PtdIns(3)P in insulin-stimulated glucose transport. Mol Endocrinol (2003) 1.15
Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood (2004) 1.14
A FRET analysis to unravel the role of cholesterol in Rac1 and PI 3-kinase activation in the InlB/Met signalling pathway. Cell Microbiol (2006) 1.13
UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal. J Biol Chem (2005) 1.13
Rituximab inhibits B-cell receptor signaling. Blood (2009) 1.13
Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood (2010) 1.12
The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol (2007) 1.11
Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica (2009) 1.11
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol (2014) 1.11
Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid (2008) 1.10
Alteration of epithelial structure and function associated with PtdIns(4,5)P2 degradation by a bacterial phosphatase. J Gen Physiol (2007) 1.07
Molecular networks linked by Moesin drive remodeling of the cell cortex during mitosis. J Cell Biol (2011) 1.07
PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood (2007) 1.06
Cutting edge: Dok-1 and Dok-2 adaptor molecules are regulated by phosphatidylinositol 5-phosphate production in T cells. J Immunol (2009) 1.06
Direct detection of Staphylococcus osteoarticular infections by use of Xpert MRSA/SA SSTI real-time PCR. J Clin Microbiol (2011) 1.05
Integrin-dependent interaction of lipid rafts with the actin cytoskeleton in activated human platelets. J Cell Sci (2005) 1.05
Tumor necrosis factor-alpha inhibits hTERT gene expression in human myeloid normal and leukemic cells. Blood (2005) 1.05
Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood (2013) 1.04
Deficiency of Src homology 2 domain-containing inositol 5-phosphatase 1 affects platelet responses and thrombus growth. J Clin Invest (2007) 1.04
Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy. Cancer Res (2009) 1.03
Phosphoinositide phosphatases in a network of signalling reactions. Pflugers Arch (2007) 1.03
Shigella flexneri infection generates the lipid PI5P to alter endocytosis and prevent termination of EGFR signaling. Sci Signal (2011) 1.02
A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK. Blood (2006) 1.02
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol (2010) 1.02
Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. Breast Cancer Res Treat (2007) 1.02